CATIE and CUtLASS (UK): Is it time psychiatrists start changing their practice?- the debate goes on!

Indian Journal of Psychiatry

Volumn 51, Issue 2, 2009, Pages 161-162

  Dasgupta, Rupak ^a   Dasgupta, Charu ^a  

^a Calderstones NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; ZIPRASIDONE;

CLINICAL ASSESSMENT; CLINICAL TRIAL; COMMUNITY CARE; CROSS-SECTIONAL STUDY; HEALTH CARE COST; HUMAN; INTERVENTION STUDY; LETTER; LONGITUDINAL STUDY; MEDICINE; PRACTICE GUIDELINE; PSYCHIATRIST; QUALITY OF LIFE; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TREATMENT DURATION; TREATMENT INDICATION; UNITED KINGDOM; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 77953397813     PISSN: 00195545     EISSN: 19983794     Source Type: Journal    
DOI: 10.4103/0019-5545.49464     Document Type: Letter

References (2)

1. Lieberman JA, Stroup S, McEvoy JR Swartz MS, Rosenheck RA, Perkins DO, et ai. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223
2. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KR et al. Randomised controlled trial of effect on quality of life of second- vs first generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006;63:1079-1087